Abstract
Amyotrophic lateral sclerosis (ALS) is a multifactorial disease, characterized by a progressive loss of motor neurons that eventually leads to paralysis and death. The current ALS-approved drugs modestly change the clinical course of the disease. The mechanism by which motor neurons progressively degenerate remains unclear but entails a non-cell autonomous process. Astrocytes impaired biological functionality were implicated in multiple neurodegenerative diseases, including ALS, frontotemporal dementia (FTD), Parkinson’s disease (PD), and Alzheimer disease (AD). In ALS disease patients, A1 reactive astrocytes were found to play a key role in the pathology of ALS disease and death of motor neurons, via loss or gain of function or acquired toxicity. The contribution of astrocytes to the maintenance of motor neurons by diverse mechanisms makes them a promising therapeutic candidate for the treatment of ALS. Therapeutic approaches targeting at modulating the function of endogenous astrocytes or replacing lost functionality by transplantation of healthy astrocytes, may contribute to the development of therapies which might slow down or even halt the progression ALS diseases. The proposed mechanisms by which astrocytes can potentially ameliorate ALS progression and the status of ALS clinical studies involving astrocytes are discussed.
Introduction
In Amyotrophic lateral sclerosis (ALS), selective degeneration of both upper and lower motor neurons (MNs) takes place in the central nervous system. Death of MNs leads to rapid and progressive paralysis of target muscles, which causes death within 3–5 years from disease onset, usually due to respiratory failure (). The degeneration of MNs is associated with multiple pathophysiological processes including, mitochondrial dysfunction, protein aggregation and formation of inclusion bodies, impairment in RNA processing, elevation in reactive oxygen species (ROS) levels, lack of axonal transport, disruption of the neuromuscular junction and demyelination (Robberecht and Philips, 2013).
The causes for ALS disease are not well understood. The main pathological characteristic of ALS is the accumulation of misfolded proteins and cytoplasmic inclusions in MNs and glial cells, in both motor cortex and spinal cord (Rowland and Shneider, 2001). Around 10–15% of ALS cases are with family history (i.e., familial), and the other cases without family history but still might be genetic (i.e., sporadic) (). Familial ALS (fALS) includes mutations of Cu/Zn superoxide dismutase (Rosen, 1993), TAR-DNA-binding protein of 43 kDa (Neumann et al., 2006), fused in sarcoma (Fus) (; Vance et al., 2009) and amplification of hexanucleotide (GGGGCC) repeat expansions in the chromosome 9 open reading frame 72 (C9orf72) (; Renton et al., 2011). In these mutations, misfolded mutated proteins are spreading (i.e., TDP-43, hSOD1, and FUS), and their aggregation induces severe neuropathology (). Interestingly, some of these misfolded proteins are not confined to the familial form of the disease where the mutation is known, but also found in sporadic ALS (e.g., TDP-43 inclusions are found in 97% of sALS patients) (Prasad et al., 2019). The mechanism by which ALS mutated proteins become toxic to MNs may share some similarities with prion aggregation and propagation. For example, C9orf72 RNA can be translated into five different dipeptide repeat (DPR) proteins (Mori et al., 2013a,b) that can spread between cells, similar to TDP-43 misfolded protein (Westergard et al., 2016). Toxicity by C9orf72 mutation can also be facilitated by transcription into long repetitive RNA that forms foci of sense or antisense RNA, which segregate RNA Binding Proteins (RBPs) and interfere with their biological activities (; ; ; Mizielinska et al., 2013; Wen et al., 2017). In addition to ALS, the role of C9orf72 was also identified as the major genetic cause of frontotemporal dementia (FTD) and FTD-ALS (; Renton et al., 2011; Vatsavayai et al., 2019). Furthermore, TDP-43 proteinopathy now also constitutes 45% of all FTD molecular pathologies (; ; ). Misfolded protein inclusions are not restricted to ALS and FTD and were also reported in other neurological diseases such as Parkinson’s disease (Trist et al., 2017, 2018), Alzheimer’s disease (; Nag et al., 2015), and Huntington disease ().
MNs are the main cells that die in ALS. MNs are substantially large cells with axon extensions that reach far distance locations (i.e., from motor cortex to spinal cord and target muscle) (Ragagnin et al., 2019). The size and function of these cells force them to be more active as compared to other cell types in the nervous system, in terms of cytoskeletal dynamics, energy consumption, RNA metabolism, and proteostasis (Vandoorne et al., 2018). Consequently, MNs are more vulnerable to changes in homeostasis, especially to proteinaceous aggregates (Weishaupt et al., 2016).
The key players in maintaining and supporting MN survival in the central nervous system are astrocytes. Astrocytes are the most common cells in the CNS and have multiple functions. In healthy conditions astrocytes regulate the concentration of different neurotransmitters and ions, supply various metabolites and energy, regulate osmolarity, modulate synaptic activity, secrete neurotrophic and neuroprotective factors, promote neurogenesis (; Verkhratsky et al., 2017) and remyelination (), play a role in immune-modulation () and blood-brain barrier formation (Sweeney et al., 2019) as well as in the glymphatic system ().
Role and Therapeutic Potential of Astrocytes in ALS
Upon insult, stress, or injury in the CNS, astrocytes enter a reactive state, characterized by changes in their morphology and profile of gene expression. Depending on the signal, astrocytes can transform into reactive A1-type neurotoxic astrocytes, or neuroprotective A2-type astrocytes (). For example, Neuroinflammatory stimuli, such as LPS, yield A1 reactive astrocytes that promote neurodegeneration and neurotoxicity. Formation of A2 is induced by ischemia, the reactive astrocytes which secrete neurotrophic factors promote neuroprotection and neural repair (; ).
Astrocytes of ALS patients present A1 type characteristics and are actors in the non-autonomous cell disease dogma in ALS (). The role of astrocytes in the progression of ALS pathology involves several mechanisms that can result in loss of homeostatic functions or gain of toxic functions. ALS Astrocytes isolated from both sporadic or familial post-mortem ALS patients were found to be toxic to healthy MNs in culture (; ). Toxicity to motor neurons was also demonstrated following coculture of direct conversion of SOD1 or C9orf72 mutated ALS patient’s fibroblasts into induced neuronal progenitor cells (iNSC) and subsequent differentiation into astrocytes (i-astrocytes) (). This toxicity might be mediated by extracellular vesicles secreted by astrocytes containing miRNA such as miR-494-3p (Varcianna et al., 2019) or proteins such as SOD1, phospho-TDP-43, and FUS (Sproviero et al., 2018). Extracellular vesicles such as exosomes and ectosmes contain a specific composition of proteins, lipids, RNA, and DNA Cells (). Recent study demonstrated that mutated astrocytes derived from C9Orf72-iPSC were toxic to MNs via downregulation of antioxidant proteins secretion, the toxic effects of astrocytes were correlated with the length of astrocyte propagation in culture, consistent with the age-related nature of ALS (). Other study showed that secretion of Tumor Necrosis Factor-Alpha (TNFα) by FUS mutated astrocytes was found to contribute MN-toxicity (). Similar results were obtained with hSOD1G93A primary astrocytes co-cultured with either WT MNs or with MNs from ALS mice (). The toxic effect on MNs was also demonstrated by the addition of astrocyte-conditioned-medium, indicating that the mechanism involves secretion of soluble molecules by mutated astrocytes ().
In contrast, healthy astrocytes protect MNs. Recent study provides evidence for the beneficial role that astrocytes play in protecting MNs in ALS (Smethurst et al., 2020). In this study, the authors first demonstrated that iPSC-derived MNs are more vulnerable to seeded TDP-43 aggregation (extracted from sALS post-mortem spinal-cord) than iPSC-derived astrocytes, indicating a cell-type-specific difference in vulnerability. This observation was further validated by the addition of proteasomal-inhibitors that enhanced the formation and propagation of TDP-43 aggregates. Under these conditions, the presence of seeded TDP-43 aggregation significantly increased MNs cell death, but to a much lesser extent in astrocytes. Next, it was shown that TDP-43 pathology spreads from MNs to astrocytes preferentially but could also be observed spreading from astrocytes to motor neurons. Interestingly, co-culture of healthy iPSC-derived astrocytes protects iPSC-derived MNs that were pre-exposed to TDP-43 aggregates for 3 days, by a significant reduction in TDP-43 aggregates and the apoptotic marker caspase-3 in MNs. This demonstrates that the presence of astrocytes protects MNs from seeded TDP-43 aggregation and its toxicity. Intriguingly, the addition of astrocyte-condition-media alone to iPSC-derived MNs, pre-exposed to TDP-43 aggregates, had similar effects on MN. Lastly, the authors demonstrated that highly purified recombinant TDP-43 oligomers reproduced the observed cell-type-specific toxicity (Smethurst et al., 2020).
Together, the data suggest that healthy astrocytes can protect MNs of ALS patients from a distance, through some secreted product. Among the most studied factors secreted by astrocytes are neurotrophins (Poyhonen et al., 2019). Neurotrophins are a family of proteins that induce the survival (), development, and function of neurons (Reichardt, 2006). This includes brain-derived neurotrophic-factor (BDNF), Nerve-growth-factor (NGF) (Schwartz and Nishiyama, 1994), Vascular-Endothelial-Growth-Factor (VEGF) (Sondell et al., 2000), neurotrophin-3 (NT-3) (Thompson et al., 2014), ciliary-neurotrophic-factor (CNTF) (Thompson et al., 2014), Glial cell-derived neurotrophic factor (GDNF) (Rowitch, 2004) and neurturin (NRTN) (Thompson et al., 2014). Lower concentration of neurtrophins were found in the CSF of ALS patients (Ramamohan et al., 2007; ; ; Shruthi et al., 2017) and its supplementation was found to protect MNs (Storkebaum et al., 2005; ; ; Shruthi et al., 2017). Astrocytes also release extracellular vesicles (Verkhratsky et al., 2016) that might target near or long-distance sites with a potential selectively to neurons (Venturini et al., 2019). For example astrocyte-derived extracellular vesicles were proven positive for neuroglobin, a protein functioning as neuroprotectant against cell insult (Venturini et al., 2019). Other groups of proteins secreted by astrocytes found to protect neurons are metalloproteases and their inhibitors () or immune-modulatory factors ().
Therapeutic Approaches Targeting Astrocytes in ALS
An interesting hypothesis is that in early-stages of ALS disease (pre-symptomatic stage), a period that may take years, there is a process of astrocyte transformation toward the A2-phenotype with neuroprotective properties. This would support the survival of MNs and delay disease onset. Then, upon disease onset and appearance of motor deficiency symptoms, probably after damage to the MN or astrocytes crosses metabolic threshold, the astrocytes acquire the A1 phenotype with neurotoxic properties. Transcriptomic data shows that astroglia in late stage of disease progression in ALS mouse model acquire A1-reactive astrocytic phenotype (). In ALS patients’ reactive astrocytes are observed in susceptible areas and the level of reactivity correlates with the neurodegeneration stage of ALS patients. These astrocytes are convoyed with numerous abnormalities of signaling pathways such as impaired lactate transport (), reduction of GLT-1 expression (), activation of p75-receptor signaling and elevation in pro-inflammatory signaling (). In G93A-SOD1 mouse model, reducing mutant SOD1 in astrocytes was found to delay the disease progression, but not disease onset indicating supporting role of astrocytes toward disease onset (Yamanaka et al., 2008).
This hypothesis raises questions of (1) What is the astrocyte profile (A1 vs. A2) at different disease stages? What characterizes the specific threshold that changes the balance between A1 to A2 astrocytes? (2) Can A2 reactive astrocytes transform directly into A1 astrocytes and vice versa? Answers to these questions may provide tools to interfere at specific transformation checkpoints and exploit astrocytes neuroprotective properties to treat ALS. Thus, targeting astrocytes offers a promising approach to treat ALS and maybe also other neurological conditions.
Astrocyte-Based Cell Therapy
One therapeutic approach is to restore the functionality of endogenous malfunctioning astrocytes by transplantation of healthy human astrocytes. This might become a double-edged sword approach, in which astrocytes provide neurotrophic factors and neuroprotective support through the reduction of misfolded proteins such as TDP-43 to the diseased MNs from one hand, and from other hand might become malfunctioning or even toxic, A1 reactive astrocytes, once they will be introduced to hostile environment ALS patients CNS enriched with aggregations of mis-folded proteins. Comprehensive preclinical studies demonstrated that transplantation of glial-precursor-cells that were generated from iPSCs, or embryonic-stem-cells (ESC), had the potential to delay disease onset and ameliorate clinical symptoms in rodent models of ALS disease (; ; ) and shown to be safe (). However, other studies show that astrocytes acquire toxic neuroinflammatory role in response to the cerebrospinal-fluid from ALS patients (). The transplantation of human glial-restricted progenitors did not result in motor neuron protection or any therapeutic benefits on functional outcome measures (). Transplantation of genetically modified GDNF neural-stem cells presented efficient delivery of GDNF and preservation of motor neurons, however, MNs survival was not accompanied by continued innervation of muscle end-plates and thus resulted in no improvement in ipsilateral limb use (Suzuki et al., 2007). The difference observed between the therapeutic effect of transplanted cells might reside from difference in the population of astrocytes and their progenitors and should be further investigated. These encouraging results led to the currently ongoing first-in-human phase I/IIa clinical study to evaluate the safety and efficacy of intrathecal transplantation of clinical-grade human astrocytes (AstroRx®) derived from human ESC in patients with ALS (ClinicalTrials.gov ID-NCT03482050). The advantage of intrathecal cell injection to cerebrospinal fluid is the distribution of human astrocytes throughout the neural axis, where the cells can reach and exert their effects on both upper and lower MNs. In addition, lumbar puncture is a standard clinical procedure and is generally safe. The mechanisms by which the transplanted astrocytes act still need to be fully elucidated. Most likely the astrocytes act by secreting neuroprotective factors that diffuse to the MNs (; ; Thomsen et al., 2018). But many questions remain: Where they attach? Can astrocytes migrate from the CSF into the CNS-parenchyma and reach MNs? Will the astrocytes maintain their A2 characteristics in the hostile CNS environment of ALS or might transform to A1-phenotype further affecting disease course? How long will the transplanted astrocytes survive? Will they transform into the A1 state? The precise mechanisms of action that contribute to the astrocytes’ effects in vivo still need to be fully understood, to optimize the potential benefit of these cells.
In another study, neural progenitor cells that were manipulated to overexpress glial cell-line derived neurotrophic factor (GDNF) enhanced the survival of MNs survival and attenuated the progression of the disease phenotype after their injection into the spinal cord () or motor cortex (Thomsen et al., 2018) of ALS rat model. These encouraging results led to a Phase I/IIa clinical trial (ClinicalTrials.gov ID-NCT02943850) aiming to assess the safety of transplantation of GDNF-producing human astrocyte-precursors into the spinal-cord lumbar segment of ALS patients. Finally, a phase-I/IIa clinical trial (ClinicalTrials.gov ID-NCT02478450) will explore the safety of transplanting Human Glial-Restricted-Progenitor Cells (Q-Cells®) into the cervical or lumbar region of the spinal cord in subjects with ALS ().
In these clinical trials, the cells are transplanted locally into the ventral horn (lumbar or cervical regions) in close vicinity to lower MNs. This might allow the cells to directly exert their therapeutic activity on a specific set of neurons as compared to the intrathecal approach.
Cell-Based Therapy Using Mesenchymal Stem Cells
Another cell-based therapy approach is the use of mesenchymal-stem-cells (MSC). MSC are adult multipotent-precursors that can be derived from bone-marrow or placenta, with the potential to differentiate into osteocytes, chondrocytes, fibroblasts, and adipocytes (Pittenger et al., 1999). MSC are not natural residence of the CNS but can be induced to secrete some of the neurotrophic factors secreted by astrocytes (). Recently, single-dose transplantation of autologous MSC that were induced to secrete neurotrophic factors (NurOwn) showed that single combined intramuscular and intrathecal transplantation of MSC-NTF cells demonstrated early promising signs of efficacy and shown to be safe (ClinicalTrials.gov ID NCT02017912) (). These results lead to the ongoing multi-dose phase-III clinical trial in rapidly progressing ALS patients (ClinicalTrials.gov ID-NCT03280056). Preclinical studies in ALS animal model showed that transplantation of MSCs, have the potential to reduce MNs death, prolong animal survival and improved motor performance over sham-injected animals (Suzuki et al., 2008; ; Uccelli et al., 2012; ). Intrathecal injection of autologous undifferentiated bone-marrow-derived MSCs (NEURONATA-R) to ALS patients (ClinicalTrials.gov ID-NCT01363401) resulted in stabilization of the ALSFRS-R score in all patients over 6 months after first cell injection. ALSo, levels of CSF immunomodulatory cytokines such as IL-10, TGF-β, and IL-6 were increased after MSC injection, this suggest that the effect of MSC treatment on ALS patients might be mediated by an immune response (Oh et al., 2015).
Other Strategies Targeting Astrocytes Activity
Compounds that can improve endogenous astrocyte functionality are also being tested. For example, a group of compounds that encompass astrocytic glutamate uptake. Excessive activation of glutamate receptor in MNs can result in cell death (). Astrocytes uptake glutamate through EAAT2 (GLT-1) transporter, thus, increasing GLT-1 transporter expression in astrocytes may improve the survival of MNs. Compounds such as Class II HDAC inhibitor MC1568 (), pyridazine derivative LDN/OSU-0212320 (), b-lactam antibiotics (e.g., ceftriaxone) (Rothstein et al., 2005), neuroimmunophilin ligand (), and FDA-approved drug Riluzole () were found to enhance the expression of GLT-1 in astrocytes and delay symptoms of MN decline and in SOD1G93A mice.
Compounds aiming at targeting endogenous-astrocytes to reduce oxidative-stress are of great therapeutic potential. Increasing availability of nicotinamide-adenine-dinucleotide (NAD+), an essential redox molecule (), leads to increased resistance to oxidative-stress and decreased mitochondrial reactive oxygen production (; ). Activation of the transcription factor, erythroid-derived 2, like 2 (Nrf2) in astrocytes confers protection to neurons in culture and in vivo (Vargas et al., 2008; ). Treatment with nicotinamide-mononucleotide (NMN) or nicotinamide-riboside (NR) increases NAD+ availability in mutant hSOD1-expressing astrocytes, leading to increased resistance to oxidative-stress and reversion of their toxicity toward co-cultured MNs, through SIRT6 activity to Nrf2 activation (). Edaravon, the second FDA approved drug for ALS, is a free-radical-scavenger of peroxyl-radicals and peroxynitrite, has been shown to inhibit MNs death in vivo by reducing oxidative-stress (). In a phase-III clinical trial (ClinicalTrials.gov, NCT01492686) this drug was found safe and demonstrated safety and efficacy in ALSFRS-R (Writing and Edaravone, 2017).
Other mechanism to reduce astrocyte toxicity is by interfering with neuroinflammatory processes taking place in the progression of the disease. Pro-inflammatory cytokines and inflammatory-mediators are also linked to astrocyte-mediated toxicities. For example, an upregulation of interferon-α (IFNα) receptor in astrocytes was found in the spinal-cord of SOD1G93A mice and sALS, and reducing its expression extended survival in SOD1G93A mice (Wang et al., 2011). Additionally, mutant-SOD1 expressing astrocytes secrete IFN-γ, which induces degeneration in motor-neurons in vitro (). The pro-inflammatory mediator, prostaglandin-D2 (PGD2), has also been linked to motor neuron death in in vitro experiments using co-culture of ES-cell derived human MNs and mutant SOD1 astrocytes (). Transforming growth-factor β (TGF-β) is a multi-functional cytokine involved in many biological functions, including immune homeostasis, neurotrophic response, and microglial development (). Alterations of TGF-β signaling have been implicated in ALS due to gene expression profiles (Phatnani et al., 2013). Next, it was demonstrated that astrocyte-derived TGF-β1 is a negative-regulator of the neuroprotective inflammatory response mediated by microglia and T-lymphocytes in ALS mice (). In summary, several treatments have been tested on ALS animals with the aim of inhibiting or reducing the pro-inflammatory action of microglia and astrocytes ().
An additional way to interfere with endogenous astrocyte function is gene therapy. The challenges using these therapies are crossing blood-brain-barrier (BBB) and specifically targeting endogenous astrocytes cell population. Several clinical studies such as Tofersen (BIIB067) (), miQure (targets down regelation of C9orf72) (, ), and VM2020 (Sufit et al., 2017) are already testing a gene therapy approach in the CNS. However, the exact mechanism and effect of these therapies on astrocytes and neurons crosstalk and functionality should be further investigated.
Conclusion and Open Questions
In conclusion, astrocytes play a central role in ALS and other neurodegenerative diseases. Targeting astrocytes functionality using different therapeutic approaches might provide great benefit to ALS patients. Many questions are still left open, such as what defines a different subpopulation of astrocytes and their response to different pathological insults? What is the crosstalk between astrocytes and the immune system? What is the best site in the CNS for astrocyte transplantation? What is the optimal timing for transplantation during the progression of the disease as well as the dose of cells to be transplanted? Is immunosuppression required in the CNS to prevent graft rejection? Step by step, astrocytes become rising stars and show great promise in the treatment of ALS, based on preclinical studies and preliminary results from clinical trials targeting astrocytes in ALS.
Statements
Author contributions
MI, SS, and MR designed and wrote the review. All authors contributed to the article and approved the submitted version.
Conflict of interest
MI, SS, and MR were employed by company Kadimastem Ltd.
References
1
AebischerJ.CassinaP.OtsmaneB.MoumenA.SeilheanD.MeiningerV.et al (2011). IFNgamma triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1.Cell Death Differ.18754–768. 10.1038/cdd.2010.143
2
AllenN. J.ErogluC. (2017). Cell biology of astrocyte-synapse interactions.Neuron96697–708. 10.1016/j.neuron.2017.09.056
3
AraiT.HasegawaM.AkiyamaH.IkedaK.NonakaT.MoriH.et al (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.Biochem. Biophys. Res. Commun.351602–611. 10.1016/j.bbrc.2006.10.093
4
Bahat-StroomzaM.BarhumY.LevyY. S.KarpovO.BulvikS.MelamedE.et al (2009). Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease.J. Mol. Neurosci.39199–210. 10.1007/s12031-008-9166-3
5
BaldwinK. T.ErogluC. (2017). Molecular mechanisms of astrocyte-induced synaptogenesis.Curr. Opin. Neurobiol.45113–120. 10.1016/j.conb.2017.05.006
6
BelenkyP.BoganK. L.BrennerC. (2007). NAD+ metabolism in health and disease.Trends Biochem. Sci.3212–19. 10.1016/j.tibs.2006.11.006
7
BerryJ. D.CudkowiczM. E.WindebankA. J.StaffN. P.OwegiM.NicholsonK. (2019). NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results.Neurology93e2294–e2305. 10.1212/wnl.0000000000008620
8
BirgerA.Ben-DorI.OttolenghiM.TuretskyT.GilY.SweetatS.et al (2019). Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity.EBioMedicine50274–289. 10.1016/j.ebiom.2019.11.026
9
BogaertE.Van DammeP.PoesenK.DhondtJ.HersmusN.KiralyD.et al (2010). VEGF protects motor neurons against excitotoxicity by upregulation of GluR2.Neurobiol. Aging312185–2191. 10.1016/j.neurobiolaging.2008.12.007
10
BoucherieC.SchaferS.Lavand’hommeP.MaloteauxJ. M.HermansE. (2009). Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis.J. Neurosci. Res.872034–2046. 10.1002/jnr.22038
11
ButovskyO.JedrychowskiM. P.MooreC. S.CialicR.LanserA. J.GabrielyG. (2014). Identification of a unique TGF-beta-dependent molecular and functional signature in microglia.Nat. Neurosci.17131–143. 10.1038/nn.3599
12
ChenP. C.VargasM. R.PaniA. K.SmeyneR. J.JohnsonD. A.KanY. W.et al (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte.Proc. Natl. Acad. Sci. U.S.A.1062933–2938. 10.1073/pnas.0813361106
13
de PicciottoN. E.GanoL. B.JohnsonL. C.MartensC. R.SindlerA. L.MillsK. F.et al (2016). Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice.Aging Cell15522–530. 10.1111/acel.12461
14
DeepaP.ShahaniN.AlladiP. A.VijayalakshmiK.SathyaprabhaT. N.NaliniA.et al (2011). Down regulation of trophic factors in neonatal rat spinal cord after administration of cerebrospinal fluid from sporadic amyotrophic lateral sclerosis patients.J. Neural Transm.118531–538. 10.1007/s00702-010-0520-6
15
DeJesus-HernandezM.MackenzieI. R.BoeveB. F.BoxerA. L.BakerM.RutherfordN. J. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.Neuron72245–256. 10.1016/j.neuron.2011.09.011
16
Di GiorgioF. P.BoultingG. L.BobrowiczS.EgganK. C. (2008). Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.Cell Stem Cell3637–648. 10.1016/j.stem.2008.09.017
17
Di GiorgioF. P.CarrascoM. A.SiaoM. C.ManiatisT.EgganK. (2007). Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.Nat. Neurosci.10608–614. 10.1038/nn1885
18
EndoF.KomineO.Fujimori-TonouN.KatsunoM.JinS.WatanabeS.et al (2015). Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells.Cell Rep.11592–604. 10.1016/j.celrep.2015.03.053
19
FascianiI.PlutaP.Gonzalez-NietoD.Martinez-MonteroP.MolanoJ.PainoC. L.et al (2018). Directional coupling of oligodendrocyte connexin-47 and astrocyte connexin-43 gap junctions.Glia662340–2352. 10.1002/glia.23471
20
FerraiuoloL.HigginbottomA.HeathP. R.BarberS.GreenaldD.KirbyJ.et al (2011). Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis.Brain134(Pt 9), 2627–2641. 10.1093/brain/awr193
21
FerrariR.KapogiannisD.HueyE. D.MomeniP. (2011). FTD and ALS: a tale of two diseases.Curr. Alzheimer Res.8273–294. 10.2174/156720511795563700
22
FrattaP.PoulterM.LashleyT.RohrerJ. D.PolkeJ. M.BeckJ.et al (2013). Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.Acta Neuropathol.126401–409. 10.1007/s00401-013-1147-0
23
GanelR.HoT.MaragakisN. J.JacksonM.SteinerJ. P.RothsteinJ. D. (2006). Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection.Neurobiol. Dis.21556–567. 10.1016/j.nbd.2005.08.014
24
GaoJ.WangL.HuntleyM. L.PerryG.WangX. (2018). Pathomechanisms of TDP-43 in neurodegeneration.J. Neurochem.10.1111/jnc.14327[Epub ahead of print].
25
GardnerJ.GhorpadeA. (2003). Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system.J. Neurosci. Res.74801–806. 10.1002/jnr.10835
26
GelosoM. C.CorvinoV.MarcheseE.SerranoA.MichettiF.D’AmbrosiN. (2017). The dual role of microglia in ALS: mechanisms and therapeutic approaches.Front. Aging Neurosci.9:242. 10.3389/fnagi.2017.00242
27
GendronT. F.CosioD. M.PetrucelliL. (2013). c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia.Expert Opin. Ther. Targets17991–995. 10.1517/14728222.2013.818659
28
GouldT. W.OppenheimR. W. (2011). Motor neuron trophic factors: therapeutic use in ALS?Brain Res. Rev.671–39. 10.1016/j.brainresrev.2010.10.003
29
GurunathanS.KangM. H.JeyarajM.QasimM.KimJ. H. (2019). Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes.Cells8:307. 10.3390/cells8040307
30
Haidet-PhillipsA. M.HesterM. E.MirandaC. J.MeyerK.BraunL. (2011). Frakes, Astrocytes from familial and sporadic ALS patients are toxic to motor neurons.Nat. Biotechnol.29824–828. 10.1038/nbt.1957
31
HardimanO.van den BergL. H.KiernanM. C. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis.Nat. Rev. Neurol.7639–649.
32
HarlanB. A.PeharM.KilloyK. M.VargasM. R. (2019). Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1.FASEB J.337084–7091. 10.1096/fj.201802752r
33
HarlanB. A.PeharM.SharmaD. R.BeesonG.BeesonC. C.VargasM. R. (2016). Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1).J. Biol. Chem.29110836–10846. 10.1074/jbc.m115.698779
34
HashiokaS.KlegerisA.SchwabC.McGeerP. L. (2009). Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells.Neurobiol. Aging301924–1935. 10.1016/j.neurobiolaging.2008.02.019
35
HempsteadB. L. (2006). Dissecting the diverse actions of pro- and mature neurotrophins.Curr. Alzheimer Res.319–24. 10.2174/156720506775697061
36
HergesheimerR. C.ChamiA. A.de AssisD. R.Vourc’hP.AndresC. R.CorciaP.et al (2019). The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?Brain1421176–1194. 10.1093/brain/awz078
37
IlievaH.PolymenidouM.ClevelandD. W. (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.J. Cell Biol.187761–772. 10.1083/jcb.200908164
38
ItoH.WateR.ZhangJ.OhnishiS.KanekoS.ItoH.et al (2008). Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.Exp. Neurol.213448–455. 10.1016/j.expneurol.2008.07.017
39
IzraelM.SlutskyS. G.AdmoniT.CohenL.GranitA.HassonA. (2018). Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models.Stem Cell Res. Ther.9:152.
40
JhaM. K.JoM.KimJ. H.SukK. (2019). Microglia-astrocyte crosstalk: an intimate molecular conversation.Neuroscientist25227–240. 10.1177/1073858418783959
41
JosephsK. A.MurrayM. E.WhitwellJ. L.ParisiJ. E.PetrucelliL.JackC. R.et al (2014). Staging TDP-43 pathology in Alzheimer’s disease.Acta Neuropathol.127441–450.
42
KiaA.McAvoyK.KrishnamurthyK.TrottiD.PasinelliP. (2018). Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha.Glia661016–1033. 10.1002/glia.23298
43
KiernanM. C.VucicS.CheahB. C.TurnerM. R.EisenA.HardimanO.et al (2011). Amyotrophic lateral sclerosis.Lancet377942–955.
44
KleinS. M.BehrstockS.McHughJ.HoffmannK.WallaceK.SuzukiM.et al (2005). GDNF delivery using human neural progenitor cells in a rat model of ALS.Hum. Gene Ther.16509–521. 10.1089/hum.2005.16.509
45
KondoT.FunayamaM.TsukitaK.HottaA.YasudaA.NoriS.et al (2014). Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice.Stem Cell Rep.3242–249. 10.1016/j.stemcr.2014.05.017
46
KongQ.ChangL. C.TakahashiK.LiuQ.SchulteD. A.LaiL.et al (2014). Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection.J. Clin. Investig.1241255–1267. 10.1172/jci66163
47
KrakoraD.MulcroneP.MeyerM.LewisC.BernauK.GowingG.et al (2013). Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model.Mol. Ther.211602–1610. 10.1038/mt.2013.108
48
KwiatkowskiT. J.Jr.BoscoD. A.LeclercA. L.TamrazianE.VanderburgC. R.RussC.et al (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.Science3231205–1208.
49
Lagier-TourenneC.PolymenidouM.HuttK. R.VuA. Q.BaughnM.HuelgaS. C. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.Nat. Neurosci.151488–1497. 10.1038/nn.3230
50
LapucciA.CavoneL.BuonvicinoD.FeliciR.GeraceE.ZwergelC.et al (2017). Effect of class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice.Neurosci. Lett.656120–125. 10.1016/j.neulet.2017.07.033
51
LeporeA. C.DejeaC.CarmenJ.RauckB.KerrD. A.SofroniewM. V.et al (2008). Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration.Exp. Neurol.211423–432. 10.1016/j.expneurol.2008.02.020
52
LeporeA. C.O’DonnellJ.KimA. S.WilliamsT.TutejaA.RaoM. S.et al (2011). Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS.PLoS One6:e25968. 10.1371/journal.pone.0025968
53
LiddelowS.BarresB. (2015). SnapShot: astrocytes in health and disease.Cell1621170–1170.e1. 10.1016/j.cell.2015.08.029
54
LiddelowS. A.BarresB. A. (2017). Reactive astrocytes: production, function, and therapeutic potential.Immunity46957–967. 10.1016/j.immuni.2017.06.006
55
LiuZ.XuY.ZhangX.MiaoJ.HanJ.ZhuZ. (2019). Riluzole blocks HU210-facilitated ventral tegmental long-term depression by enhancing glutamate uptake in astrocytes.Neurosci. Lett.704201–207. 10.1016/j.neulet.2019.04.021
56
LouveauA.PlogB. A.AntilaS.AlitaloK.NedergaardM.KipnisJ. (2017). Understanding the functions and relationships of the glymphatic system and meningeal lymphatics.J. Clin. Investig.1273210–3219. 10.1172/jci90603
57
MarchettoM. C.MuotriA. R.MuY.SmithA. M.CezarG. G.GageF. H. (2008). Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells.Cell Stem Cell3649–657. 10.1016/j.stem.2008.10.001
58
MarconiS.BonaconsaM.ScambiI.SquintaniG. M.RuiW.TuranoE. (2013). Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model.Neuroscience248333–343. 10.1016/j.neuroscience.2013.05.034
59
MartierR.LiefhebberJ. M.Garcia-OstaA.MiniarikovaJ.Cuadrado-TejedorM.EspelosinM.et al (2019a). Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy.Mol. Ther. Nucleic Acids1626–37. 10.1016/j.omtn.2019.02.001
60
MartierR.LiefhebberJ. M.MiniarikovaJ.van der ZonT.SnapperJ.KolderI.et al (2019b). Artificial MicroRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients.Mol. Ther. Nucleic Acids14593–608. 10.1016/j.omtn.2019.01.010
61
MartoranaF.BrambillaL.ValoriC. F.BergamaschiC.RoncoroniC.AronicaE.et al (2012). The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals.Hum. Mol. Genet.21826–840. 10.1093/hmg/ddr513
62
McAlaryL.PlotkinS. S.YerburyJ. J.CashmanN. R. (2019). Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis.Front. Mol. Neurosci.12:262. 10.3389/fnmol.2019.00262
63
MeyerK.FerraiuoloL.MirandaC. J.LikhiteS.McElroyS.RenuschS. (2014). Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.Proc. Natl. Acad. Sci. U.S.A.111829–832. 10.1073/pnas.1314085111
64
MillerS. J.ZhangP. W.GlatzerJ.RothsteinJ. D. (2017). Astroglial transcriptome dysregulation in early disease of an ALS mutant SOD1 mouse model.J. Neurogenet.3137–48. 10.1080/01677063.2016.1260128
65
MillerT. M.PestronkA.DavidW.RothsteinJ.SimpsonE.AppelS. H.et al (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.Lancet Neurol.12435–442. 10.1016/s1474-4422(13)70061-9
66
MishraP. S.DhullD. K.NaliniA.VijayalakshmiK.SathyaprabhaT. N.AlladiP. A.et al (2016). Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients.J. Neuroinflammation13:212.
67
MizielinskaS.LashleyT.NoronaF. E.ClaytonE. L.RidlerC. E.FrattaP.et al (2013). C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci.Acta Neuropathol.126845–857. 10.1007/s00401-013-1200-z
68
MoriK.ArzbergerT.GrasserF. A.GijselinckI.MayS.RentzschK.et al (2013a). Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins.Acta Neuropathol.126881–893. 10.1007/s00401-013-1189-3
69
MoriK.WengS. M.ArzbergerT.MayS.RentzschK.KremmerE.et al (2013b). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.Science3391335–1338. 10.1126/science.1232927
70
NagS.YuL.CapuanoA. W.WilsonR. S.LeurgansS. E.BennettD. A.et al (2015). Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.Ann. Neurol.77942–952. 10.1002/ana.24388
71
NeumannM.SampathuD. M.KwongL. K.TruaxA. C.MicsenyiM. C.ChouT. T. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.Science314130–133.
72
OhK. W.MoonC.KimH. Y.OhS. I.ParkJ.LeeJ. H.et al (2015). Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.Stem Cells Transl. Med.4590–597. 10.5966/sctm.2014-0212
73
PhatnaniH. P.GuarnieriP.FriedmanB. A.CarrascoM. A.MuratetM.O’KeeffeS.et al (2013). Intricate interplay between astrocytes and motor neurons in ALS.Proc. Natl. Acad. Sci. U.S.A.110E756–E765.
74
PittengerM. F.MackayA. M.BeckS. C.JaiswalR. K.DouglasR.MoscaJ. D.et al (1999). Multilineage potential of adult human mesenchymal stem cells.Science284143–147. 10.1126/science.284.5411.143
75
PoyhonenS.ErS.DomanskyiA.AiravaaraM. (2019). Effects of neurotrophic factors in glial cells in the central nervous system: expression and properties in neurodegeneration and injury.Front. Physiol.10:486. 10.3389/fphys.2019.00486
76
PrasadA.BharathiV.SivalingamV.GirdharA.PatelB. K. (2019). Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis.Front. Mol. Neurosci.12:25. 10.3389/fnmol.2019.00025
77
RagagninA. M. G.ShadfarS.VidalM.JamaliM. S.AtkinJ. D. (2019). Motor neuron susceptibility in ALS/FTD.Front. Neurosci.13:532. 10.3389/fnins.2019.00532
78
RamamohanP. Y.Gourie-DeviM.NaliniA.ShobhaK.RamamohanY.JoshiP.et al (2007). Cerebrospinal fluid from amyotrophic lateral sclerosis patients causes fragmentation of the Golgi apparatus in the neonatal rat spinal cord.Amyotroph. Lateral Scler.879–82. 10.1080/08037060601145489
79
ReichardtL. F. (2006). Neurotrophin-regulated signalling pathways.Philos. Trans. R. Soc. Lond. B Biol. Sci.3611545–1564. 10.1098/rstb.2006.1894
80
RentonA. E.MajounieE.WaiteA.Simon-SanchezJ.RollinsonS.GibbsJ. R.et al (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.Neuron72257–268.
81
RobberechtW.PhilipsT. (2013). The changing scene of amyotrophic lateral sclerosis.Nat. Rev. Neurosci.14248–264. 10.1038/nrn3430
82
RosenD. R. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.Nature36259–62.
83
RothsteinJ. D.PatelS.ReganM. R.HaenggeliC.HuangY. H.BerglesD. E.et al (2005). Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.Nature43373–77. 10.1038/nature03180
84
RowitchD. H. (2004). Glial specification in the vertebrate neural tube.Nat. Rev. Neurosci.5409–419. 10.1038/nrn1389
85
RowlandL. P.ShneiderN. A. (2001). Amyotrophic lateral sclerosis.N. Engl. J. Med.3441688–1700.
86
SchwartzJ. P.NishiyamaN. (1994). Neurotrophic factor gene expression in astrocytes during development and following injury.Brain Res. Bull.35403–407. 10.1016/0361-9230(94)90151-1
87
ShruthiS.SumithaR.VargheseA. M.AshokS.Chandrasekhar SagarB. K.SathyaprabhaT. N.et al (2017). Brain-derived neurotrophic factor facilitates functional recovery from ALS-cerebral spinal fluid-induced neurodegenerative changes in the NSC-34 motor neuron cell line.Neurodegener. Dis.1744–58. 10.1159/000447559
88
SmethurstP.RisseE.TyzackG. E.MitchellJ. S.TahaD. M.ChenY. R.et al (2020). Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis.Brain143430–440. 10.1093/brain/awz419
89
SondellM.SundlerF.KanjeM. (2000). Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor.Eur. J. Neurosci.124243–4254. 10.1046/j.0953-816x.2000.01326.x
90
SprovieroD.La SalviaS.GianniniM.CrippaV.GagliardiS.BernuzziS.et al (2018). Pathological proteins are transported by extracellular vesicles of sporadic amyotrophic lateral sclerosis patients.Front. Neurosci.12:487. 10.3389/fnins.2018.00487
91
StorkebaumE.LambrechtsD.DewerchinM.Moreno-MurcianoM. P.AppelmansS.OhH.et al (2005). Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.Nat. Neurosci.885–92. 10.1038/nn1360
92
SufitR. L.Ajroud-DrissS.CaseyP.KesslerJ. A. (2017). Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.Amyotroph. Lateral Scler. Frontotemporal Degener.18269–278. 10.1080/21678421.2016.1259334
93
SuzukiM.McHughJ.TorkC.ShelleyB.HayesA.BellantuonoI.et al (2008). Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS.Mol. Ther.162002–2010. 10.1038/mt.2008.197
94
SuzukiM.McHughJ.TorkC.ShelleyB.KleinS. M.AebischerP.et al (2007). GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS.PLoS One2:e689. 10.1371/journal.pone.0000689
95
SweeneyM. D.ZhaoZ.MontagneA.NelsonA. R.ZlokovicB. V. (2019). Blood-brain barrier: from physiology to disease and back.Physiol. Rev.9921–78. 10.1152/physrev.00050.2017
96
ThompsonC. L.NgL.MenonV.MartinezS.LeeC. K.GlattfelderK. (2014). A high-resolution spatiotemporal atlas of gene expression of the developing mouse brain.Neuron83309–323.
97
ThomsenG. M.AvalosP.MaA. A.AlkaslasiM.ChoN.WyssL.et al (2018). Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis.Stem Cells361122–1131. 10.1002/stem.2825
98
TristB. G.DaviesK. M.CottamV.GenoudS.OrtegaR.RoudeauS.et al (2017). Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain.Acta Neuropathol.134113–127. 10.1007/s00401-017-1726-6
99
TristB. G.FifitaJ. A.FreckletonS. E.HareD. J.LewisS. J. G.HallidayG. M.et al (2018). Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene.Acta Neuropathol.135155–156. 10.1007/s00401-017-1779-6
100
UccelliA.MilaneseM.PrincipatoM. C.MorandoS.BonifacinoT.VerganiL.et al (2012). Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis.Mol. Med.18794–804. 10.2119/molmed.2011.00498
101
VanceC.RogeljB.HortobagyiT.De VosK. J.NishimuraA. L.SreedharanJ. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.Science3231208–1211.
102
VandoorneT.De BockK.Van Den BoschL. (2018). Energy metabolism in ALS: an underappreciated opportunity?Acta Neuropathol.135489–509. 10.1007/s00401-018-1835-x
103
VarciannaA.MyszczynskaM. A.CastelliL. M.O’NeillB.KimY.TalbotJ. (2019). Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS.EBioMedicine40626–635. 10.1016/j.ebiom.2018.11.067
104
VargasM. R.JohnsonD. A.SirkisD. W.MessingA.JohnsonJ. A. (2008). Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.J. Neurosci.2813574–13581. 10.1523/jneurosci.4099-08.2008
105
VatsavayaiS. C.NanaA. L.YokoyamaJ. S.SeeleyW. W. (2019). C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies.Acta Neuropathol.1371–26. 10.1007/s00401-018-1921-0
106
VenturiniA.PassalacquaM.PelassaS.PastorinoF.TedescoM.CorteseK.et al (2019). Exosomes from astrocyte processes: signaling to neurons.Front. Pharmacol.10:1452. 10.3389/fphar.2019.01452
107
VerkhratskyA.MatteoliM.ParpuraV.MothetJ. P.ZorecR. (2016). Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion.EMBO J.35239–257. 10.15252/embj.201592705
108
VerkhratskyA.ZorecR.ParpuraV. (2017). Stratification of astrocytes in healthy and diseased brain.Brain Pathol.27629–644. 10.1111/bpa.12537
109
WangR.YangB.ZhangD. (2011). Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model.Glia59946–958. 10.1002/glia.21167
110
WeishauptJ. H.HymanT.DikicI. (2016). Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia.Trends Mol. Med.22769–783. 10.1016/j.molmed.2016.07.005
111
WenX.WestergardT.PasinelliP.TrottiD. (2017). Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.Neurosci. Lett.63616–26. 10.1016/j.neulet.2016.09.007
112
WestergardT.JensenB. K.WenX.CaiJ.KropfE.IacovittiL.et al (2016). Cell-to-cell transmission of dipeptide repeat proteins linked to C9orf72-ALS/FTD.Cell Rep.17645–652. 10.1016/j.celrep.2016.09.032
113
WritingG.EdaravoneA. L. S. S. G. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.Lancet Neurol.16505–512.
114
YamanakaK.ChunS. J.BoilleeS.Fujimori-TonouN.YamashitaH.GutmannD. H.et al (2008). Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis.Nat. Neurosci.11251–253.
Summary
Keywords
amyotrophic lateral sclerosis, astrocytes, TDP-43 aggregates, astrocyte cell-based therapy, A1 astrocyte, A2 astrocyte
Citation
Izrael M, Slutsky SG and Revel M (2020) Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease. Front. Neurosci. 14:824. doi: 10.3389/fnins.2020.00824
Received
01 May 2020
Accepted
14 July 2020
Published
28 July 2020
Volume
14 - 2020
Edited by
Tibor Hortobágyi, University of Szeged, Hungary
Reviewed by
Valentina Bonetto, Mario Negri Pharmacological Research Institute (IRCCS), Italy; Nóra Mercedes Márkus, University of Sheffield, United Kingdom
Updates
Copyright
© 2020 Izrael, Slutsky and Revel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michal Izrael, m.izrael@kadimastem.com; michal.izrael@mail.huji.ac.il
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.